/Investor DB

Concord Health Partners — 2021 Investments

4 investments dated 2021 · listed companies and verified rows first · show all

Cedarcedar.comin𝕏Mar 2021

Cedar provides a unified patient financial platform for healthcare providers, combining billing, payments, coverage, and support powered by healthcare-specific AI.

AI & Machine LearningEnterprise SoftwareFintechHealthtechSaaS

Florian Otto(Founder)inArel Lidow(Founder)in

Co-investorsAlkeon InnovationAndreessen HorowitzKinnevikNat TurnerOak HC/FTOptum Ventures+5 more

Cedarcedar.buildMar 2021 · $200M

Cedar combines licensed architectural services with AI-driven design tools to take housing projects from site analysis through design and permitting.

AI & Machine LearningConstruction TechPropTechAustin, US

Nate Peters(Founder)in

Co-investorsAlumni VenturesAntlerCriticalityAndreessen HorowitzJP Morgan ChaseThrive Capital+1 more

Clarify Healthclarifyhealth.cominMar 2021

Clarify Health is a healthcare outcomes and analytics company that partners with health systems to align clinical, access, and financial performance across referrals, network economics, and payer contracts.

AI & Machine LearningData & InfrastructureDigital HealthHealthtechSan Francisco, US

Jean Drouin(Executive Officer, Director)inTodd Gottula(CEO & Co-Founder)in

Co-investorsAspenwoodCorewell Health VenturesInHealth VenturesMenlo VenturesSoftBank Vision FundBlackRock+4 more

Cyleracylera.comin𝕏Apr 2021 · $10M

Cylera provides a healthcare cybersecurity platform focused on connected medical devices, IoT, and IT assets, giving hospitals and health systems visibility, risk assessment, and threat detection across their environments.

CybersecurityHealthtechIoTNew York, US

Timur Ozekcin(Executive Officer, Director)inSean Abraham(Executive Officer, Director)inApostolos Bakoyiannis(Executive Officer)Owen Wilson(Director)

Co-investorsAlumni VenturesContour Venture PartnersDreamit VenturesEpsilon Health InvestorsFrontier Path VCGreat Oaks Venture Capital+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.